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CD4+ T-cell counts were further analyzed.
Results: Totally 291 HIV-infected cases were enrolled. Their mean ages
were 35.9 (standard deviation; 9.4) years, male：female ratio；254
(87.3%)：37(12.7%). Among them, 98.8% (168/170) showed CMV IgG posi-
tivity. Ninety-five patients (32.6%) had CD4+T cell count >Z500 cells/
uL; 156 patients (53.6%), >Z200 - <500cells/uL; and 40 patients
(13.7%), <200cells/uL. In addition, 23 (7.9%) patients had HIV viral load
>Z100,000 copies/ml; 98 patients (33.7%), >Z400 - <100,000; 50 pa-
tients (17.1%), >Z20 - <400; and 120 patients (41.2%), < 20 copies/ml.
Among them, 268 cases (92.1%) had negative CMV DNA detection, 16 cases
(5.5%) had detectable CMV DNA (<150 copies/mL), and 7 cases (2.4%) had
CMV DNA>150 copies/ml. Patients who had CD4+ T cell counts<200 cells/
uL have 5 times of odds ratio to develop CMV viremia, compared to sub-
jects who have CD4+ T cell counts > 500 cells/uL. Patients who had
HIV viral load >100,000 copies/ml have 129 times of odds ratio to develop
CMV viremia, compared to subjects who have HIV viral load <20
copies/ml.
Conclusion: Early initiation of highly active antiretroviral therapy would
prompt the recovery of immune deficiency, and certainly alleviate the
burden of CMV viremia.Table Demographic Features and Treatment Outcome
Characteristics MSM (NZ43) IDU and others (NZ11) P value
Age (years)PS 2-338
CLINICAL EXPERIENCES IN INTERPRETATION OF HIV-1 WESTERN BLOT
INDETERMINATE RESULTS
Kuo-Chen Weng a, Shu-Yuan Ho a, Sui-Yuan Chang a,b. aDepartments of
Laboratory Medicine, National Taiwan University Hospital, Taiwan;
bDepartment of Clinical Laboratory Sciences and Medical Biotechnology,
National Taiwan University, Taiwan
Purpose: According to the guidelines published by Taiwan Centers for Dis-
ease Control, status of HIV infection has to be confirmed by a positive West-
ern blot (WB) results after the HIV-1/2 antibody screening assay. However,
the interpretation of WB results might vary according to the package inserts
of the commercial manufacturers, which might cause disagreement between
different clinical laboratories.
Methods: The clinical outcomes of 1712 patients whose specimens were sent
for HIV WB tests between May 2006 and April 2012 were analyzed. The BIO-
RAD NEW LAV BLOT I, II was used by the Virology laboratory of the National
Taiwan University Hospital.
Results: Between the study period, a total of 1712 HIV WB-I tests were per-
formed, which include 1015 positive, 285 indeterminate, and 412 negative
results. For those who are determined as HIV WB-I positive, they are sero-
positive for GP160 (NZ1,014), GP110/120 (NZ995), P68/66 (NZ973), P55
(NZ885), P52/51 (NZ941), GP41 (NZ945), P40 (NZ602), P34/31
(NZ902), P24/25 (NZ937), and P18/17 (NZ679). For the indeterminate
HIV WB-I, four patterns are most common and they are P24/25 (NZ46),
P18/17 (NZ26), GP160 + P55 + P24/25 (NZ22), and P55 (NZ22). Among
the 22 patients reactive with GP160 + P55 + P24/25, 20(91%) are confirmed
with HIV infection status and two were lost of follow-up.
For HIV WB-II, among the 228 tests, none was positive. 98 are indeterminate
and 130 are negative. Most of the indeterminate HIV WB-II are sero-positive
with P26(NZ57). None of them are confirmed with HIV-2 infection at the end
of the study period.
Conclusions: Based on the study results, for those who have indeterminate
WB results, two or more interpretation criteria are suggested to help inter-
pretation, such WHO CRITERIA: 2ENV  GAG  POL and US CENTER FOR DIS-
EASE CONTROL CRITERIA: ENV + P24 / 25.Median [IQR] 34 (30e40) 43 (41e51) .011
Ongoing ART
Any 41 (95.3%) 5 (45.5%) < .001
Last HIV-1 RNA (copies/mL)
<40 32/40 (80.0%) 4/11 (36.4%) .009
HCV Genotype
GT1 11/31 (35.5%) 7/10 (70.0%) .075
GT2 18/31 (58.1%) 2/10 (20.0%) .067
GT6 0/31 (0.0%) 1/10 (10.0%) .244
Treatment Outcome
RVR 17/26 (65.4%) 3/6 (50.0%) .647PS 2-339
HIV-1 CRF08_BC MUTANTS RESISTANT TO REVERSE TRANSCRIPTASE
INHIBITORS
Hao Wu, Xiao-Min Zhang, Bo-Jian Zheng. Department of Microbiology, The
University of Hong Kong, Hong Kong
Purpose: Human immunodeficiency virus type (HIV)-1 circulating recombi-
nant form 08_BC (CRF08_BC), carrying recombinant reverse transcriptase
(RT) gene from subtype B and C, has recently become highly prevalent in
Southern China. As the number of patients infected by CRF08_BC increases,it is important to characterize the drug resistance mutations of CRF08_BC,
especially against widely used antiretrovirals.
Methods: In this study, clinically isolated virus was propagated in human pe-
ripheral blood mononuclear cells (PBMCs) with increasing concentrations of
nevirapine (NVP), efavirenz (EFV) or lamivudine (3TC).
Results: Three different resistance patterns led by initial mutations of
Y181C, E138G and Y188C were detected after in vitro selection with NVP. Vi-
rus variants with initial mutations, in combination with three other previ-
ously reported substitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I,
F116L, E138R, A139V, V189I, G190A, D218E, E203K, H221Y, F227L, N348I
and T369I) or novel mutations (V8I, S134N, C162Y, L228I, Y232H, E396G
and D404N) developed during NVP selection. EFV-associated variations con-
tained two initial mutations (L100I and Y188C) and three other mutations
(V106L, F116Y and T139V). Phenotypic analyses showed that E138R, Y181C
and G190A contributed high level resistance to NVP, while L100I and V106L
significantly reduce virus susceptibility to EFV. Y188C resulted in a 20-fold
reduction of susceptibility to both NVP and EFV. M184V was selected by
3TC as expected. This mutation, alone or with V90I or D67N, decreased
3TC susceptibility by over 1000 folds.
Conclusion: These results have brought new insight into the development of
drug-related mutations in patients and provided useful information for the
optimization of antiretroviral regimens.PS 2-340
PEGYLATED INTERFERON/RIBAVIRIN TREATMENT HIGHLY EFFECTIVE IN
HIV/HCV-COINFECTED MEN WHO HAVE SEX WITH MEN IN TAIWAN: SINGLE
MEDICAL CENTER EXPERIENCE
Wen-wei Ku a, Yea-yuan Chang b, Chih-hao Chang c, Bor-shen Hu d, Wong-
wing Wai b. aDivision of Infectious Diseases, Taipei Veterans General Hospital,
Hsinchu Branch, Hsinchu, Taiwan; bDivision of Infectious Diseases, Taipei
Veterans General Hospital, Taipei, Taiwan; cDivision of Gastroenterology,
Taipei Veterans General Hospital, Taipei, Taiwan; dDivision of Infectious
Diseases, Taipei City Hospital, Heping Branch, Taipei, Taiwan
Purpose: A recent outbreak of HCV infection has been identified among HIV-
infected men who have sex with men (MSM) worldwide, including Taiwan
since 2006. Pegylated interferon (PEG-IFN) with ribavirin (RBV) remains stan-
dard of treatment in most Asian countries. However, very few studies have
evaluated the treatment efficacy in such particular population.
Methods: We conducted a single-centered, retrospective cohort study of
HIV-1 infected patients in Northern Taiwan from 2006 to 2014. Persistent
HCV infection was diagnosed with positive anti-HCV serology and a detect-
able HCV viral load. Clinical characteristics, HIV-1 infection status, use of
antiretroviral therapy (ART), HCV genotypes, and IL-28B genotypes were
collected at baseline, during PEG-IFN plus RBV treatment, and at follow-up.
Results: Fifty-four patients had persistent HCV infection, of whom 43 were
MSM. They were significantly younger and received ART with an undetectable
HIV-1 viremia more often than the other cohort (Table). Thirty-four MSM were
eligible for treatment and had a very high sustained virological response (SVR)
rate regardless of HCV genotypes (80.0% [4/5] for GT 1, 100.0% [7/7] for non-
GT 1, p Z .417). Skin manifestations (local injection reaction and alopecia),
anemia, and depression were the most frequent adverse effects.EVR 21/21 (100.0%) 5/5 (100.0%) NA
SVR 18/19 (94.7%) 0/1 (0.0%) .100
